Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.58 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.58 |
| ▸ | APP | P05067 | 2/20 | 0.55 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.47 |
| ▸ | IAPP | P10997 | 3/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7606028 | 0.91 | ALOX5 (0.50) | CYP4F2CYP4A11APPCYP4Z1IAPP | |
| SCHEMBL3740648 | 0.88 | CYP4F2 (0.58) | CYP4F2CYP4A11APPCYP4Z1IAPP | |
| SCHEMBL490911 | 0.86 | APP (0.73) | CYP4F2CYP4A11APPCYP4Z1IAPP | |
| SCHEMBL30291871 | 0.86 | APP (0.73) | CYP4F2CYP4A11APPCYP4Z1IAPP | |
| SCHEMBL1745479 | 0.84 | ALOX5 (0.51) | APPIAPPHDAC3HDAC4HDAC1 | |
| SCHEMBL135908 | 0.84 | HDAC1 (0.51) | CYP4Z1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8984895 | 0.84 | CYP4F2 (0.61) | CYP4F2CYP4A11APPCYP4Z1IAPP | |
| SCHEMBL1549436 | 0.84 | CYP4F2 (0.61) | CYP4F2CYP4A11APPCYP4Z1IAPP | |
| SCHEMBL2432075 | 0.83 | CYP4F2 (0.59) | CYP4F2CYP4A11APPCYP4Z1IAPP | |
| SCHEMBL16049214 | 0.83 | CYP4F2 (0.54) | CYP4F2CYP4A11APPCYP4Z1PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3409671-B1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-21 | — | — | EP | disclosed |
| US-10618893-B2 | GPR120 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICALS NV (BE) | 2020-04-14 | — | — | US | disclosed |
| CN-106414434-B | Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes | 詹森药业有限公司 | 2019-12-31 | — | — | CN | disclosed |
| US-20190071435-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-07 | — | — | US | disclosed |
| EP-3409671-A1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | Janssen Pharmaceutica NV (BE) | 2018-12-05 | — | — | EP | disclosed |
| US-10118922-B2 | GPR120 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-06 | — | — | US | disclosed |
| EP-3114123-B1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-25 | — | — | EP | disclosed |
| CN-106414434-A | Isothiazole derivatives as gpr120 agonists for the treatment of type ii diabetes | 詹森药业有限公司 | 2017-02-15 | — | — | CN | disclosed |
| EP-3114123-A1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | Janssen Pharmaceutica NV (BE) | 2017-01-11 | — | — | EP | disclosed |
| EP-2970161-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | Janssen Pharmaceutica, N.V. (BE) | 2016-01-20 | — | — | EP | disclosed |
| US-7514473-B2 | Calcilytic compounds | SMITHKLINE BEECHAM, CORP. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1477472-B1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2009-01-14 | — | — | EP | disclosed |
| CN-100387576-C | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI CHEMICAL IND (JP) | 2008-05-14 | — | — | CN | disclosed |
| US-20060058391-A1 | Calcilytic compounds | SMITHKLINE BEECHAM CORPORATION | 2006-03-16 | — | — | US | disclosed |
| EP-1569892-A2 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-09-07 | — | — | EP | disclosed |
| CN-1653032-A | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI CHEMICAL IND (JP) | 2005-08-10 | — | — | CN | disclosed |
| US-6867320-B2 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-03-15 | — | — | US | disclosed |
| EP-1477472-A1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2004-11-17 | — | — | EP | disclosed |
| WO-2004047751-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071435-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GLP1R, GCGR | CYP4F2 2590/4885CYP4A11 631/4885APP 3057/4885 |
| US-20060058391-A1 | Calcilytic compounds | SOST, CALCB, CALCR | CYP4F2 2478/4885CYP4A11 3736/4885APP 1632/4885 |
| US-10118922-B2 | GPR120 agonists for the treatment of type II diabetes | GPR119, GLP1R, GCGR | CYP4F2 2590/4885CYP4A11 631/4885APP 3057/4885 |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | PTGER1, CYSLTR1, PTGS1 | CYP4F2 2961/4885CYP4A11 385/4885APP 2393/4885 |
| US-10618893-B2 | GPR120 agonists for the treatment of type II diabetes | GPR119, GLP1R, GCGR | CYP4F2 2590/4885CYP4A11 631/4885APP 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.